Clinical trials: Liver, Cancer of, Non-Resectable
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic)
CREO - Microwave Ablation Feasibility Study
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer.
- Conditions
- Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III
- Trial name
- NCT07817147
- Testing
- EUS-Guided MWA Device
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Banner Health
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01899261
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Montefiore Medical Center
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
- Trial name
- NCT05953337
- Testing
- EYE90 Microspheres Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- ABK Biomedical
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
Surgery for hilar cholangiocarcinoma (phCCA) remains a significant challenge. The minority of patients who are eligible for resection are exposed to high procedure-related morbidity and mortality, and despite apparent R0…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent, Liver Transplantation
- Trial name
- SURE-LT (NCT06850753)
- Testing
- Liver transplantation after en bloc resection of the liver and pancreas
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Hepatocellular Carcinoma, Solid Tumor
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients…
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
- Trial name
- MYCHELANGELO I (NCT05497453)
- Testing
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two
- Where
- 15 sites in United States, Hong Kong and 3 more
- Volunteers
- 24 people
- Sponsor
- Omega Therapeutics
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Cholangiocarcinoma Non-resectable, Gall Bladder Cancer
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
The goal of this clinical randomized controlled trial is to perform primary percutaneous stenting (PPS) in patients with malignant hilar biliary obstruction (MHBO).
- Conditions
- Cholangiocarcinoma Non-resectable, Gall Bladder Cancer, Liver Metastasis, Malignant Hilar Stricture
- Trial name
- TESLA RCT (NCT06671418)
- Testing
- Primary percutaneous stenting (PPS), Endoscopic biliary drainage
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
- Trial name
- TIKET (NCT06487663)
- Testing
- TACE with ICI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Primary Liver Cancer, Non-Resectable Hepatocellular Carcinoma
MRI-guided Holmium-166 Radioembolization
To investigate the safety and feasibility of a personalized Ho-166-PLLA-MS TARE approach by using MRI guidance in inoperable patients with HCC.
- Trial name
- EMERITUS-2 (NCT05609448)
- Testing
- MRI-guided radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver, Cancer of, Non-Resectable
TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
Protocol Synopsis Title A Humanitarian Device Exemption Use Protocol of TheraSphere® For Treatment of Unresectable Primary or Secondary Liver Neoplasia Supplier BTG International Canada Inc.
- Trial name
- NCT04090645
- Testing
- TheraSphere
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Methodist Health System
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Liver, Cancer of, Non-Resectable
QuiremSpheres Observational Study
The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT…
- Trial name
- Hope166 (NCT03563274)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheres®
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Terumo Europe N.V.
Liver Cell Carcinoma Non-resectable
Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer in men and the seventh in women and is the third most common cause of death from cancer worldwide.
- Trial name
- DEBDOX (NCT01891539)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology